The European Health Data Space should lead to the empowerment of citizens and support for research and innovation.
EU residents will have more control over their health data,
being able to access it electronically and share it across borders. This
is particularly beneficial for cross-border healthcare, allowing
individuals to access medical records and receive care seamlessly
throughout the EU.
The EHDS promotes the secondary
use of health data for research, innovation, and policy-making.
Researchers and innovators will be able to access health data more easily
and securely, which could drive the development of new treatments, medical
devices, and AI applications.
The main objectives of the European Health Data Space (source: excerpt from the Communication from the Commission to the European Parliament and the Council: The European Health Data Space: Harnessing the power of health data for people, patients, and innovation):
The European Health Data Space (EHDS) has advanced significantly since the initial concept of a digital transformation in healthcare across all EU member states.
CTIS byl
zřízen farmaceutickým zákonem v rámci Nařízení o klinických studiích (Nařízení (EU) č. 536/2014) a po 30.
lednu 2025 kompletně nahradí původní systém pro klinické studie EudraCT
(Databáze klinických studií orgánů pro regulaci léčiv Evropské unie).
Evropská léková agentura (EMA) průběžně
publikuje zprávy, jak proces přechodu na nový systém pokračuje.
V předchozím článku jsme
ukazovali, jaká byla situace v únoru 2024, v tomto článku jsme informace o počtu
podání a rozhodnutí o přechodu aktualizovali ke konci srpna 2024.
Obr. č. 1 – Změny v počtu
podaných žádostí, resp. v počtu podání, kde již bylo rozhodnuto, v porovnání
s předchozím měsícem
CTIS was established by pharmaceutical law in the Clinical Trials Regulation (Regulation (EU) No 536/2014) and will completely replace the previous system for clinical trials EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) after 30th January 2025. CTIS supports interactions between clinical trial sponsors (researchers or companies that run a clinical trial and collect and analyse the data) and regulatory authorities in the EU Member States and EEA countries, throughout the lifecycle of a clinical trial.
CTIS is guaranteed by European Medicines
agency (EMA) and works in a secured workspace.
The important milestones for clinical trials:
CT starts after
30th January 2023 – the submission must be completed through CTIS
CT ends before
30th January 2025 – CT is maintained in EudraCT or national
systems
CT is expected
to continue after 30th January 2025 – transition from the EudraCT or
national systems to the CTIS is necessary.
CTIS podporuje interakce mezi sponzory klinických studií (výzkumníky nebo společnostmi, které provádějí klinickou studii a shromažďují a analyzují data) a regulačními orgány v členských státech EU...
Based on the amendment to Act
No. 235/2004 Coll., on Value Added Tax, as of January 1, 2024, there has been a
change in VAT rates, particularly impacting the increase in prices and
reimbursements for medicinal products. In the infographics, we will illustrate
how the individual rates have changed and examine the international comparison
to assess the impact on the Czech Republic.
While the standard VAT rate
remains at 21 percent, the original reduced rates of 15 percent (for medical
devices) and 10 percent (for medicinal products) have been unified into a
single 12 percent rate. The newly introduced zero rate applies exclusively to
books, although the inclusion of medicinal products could have been possible in
line with European legislation.
The infographics provides an
overview of the changes in rates as follows:
Based on the amendment to Act No. 235/2004 Coll., on Value Added Tax, as of January 1, 2024, there has been a change in VAT rates, particularly impacting the increase in prices and reimbursements...
Drug pricing and reimbursement are based on price referencing, where the foreign price in a foreign currency is converted into Czech koruna. For this purpose, it is essential to obtain the quarterly average exchange rate for the foreign exchange market, as published by the Czech National Bank.
Our new online overview provides: ✔ The required average exchange rate from the previous quarter ✔ The exchange rate development in the current quarter ✔ A monitoring focus on the 7 most commonly used European exchange rates in administrative proceedings
The key information for conducting price referencing in administrative procedures for drug pricing and reimbursement is the average exchange rate from the previous quarter. Now, you can easily...
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant sanofi-aventis, s.r.o., against the decision of the State Institute for Drug Control from 23. 3. 2021, under the no. SUKLS172396/2020:
the remainder of the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health regarding the appeal of the appelant sanofi-aventis, s.r.o. - the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant Otsuka Pharmaceutical Netherlands B. V., against the decision of the State Institute for Drug Control from 9. 4. 2021, under the no. SUKLS182256/2020:
the remainder of the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health regarding the appeal of the appelant Egis Pharmaceuticals PLC - the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant Otsuka Pharmaceutical Netherlands B. V., against the decision of the State Institute for Drug Control from 12. 4. 2021, under the no. SUKLS182359/2020:
the remainder of the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health regarding the appeal of the appelant Egis Pharmaceuticals PLC - the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant Union of Health Insurance Companies, against the decision of the State Institute for Drug Control from 10. 8. 2022, under the no. SUKLS85858/2022:
the decision under
appeal is reversed and the issue is referred back to the State Institute for
Drug Control for reappraisal.
A decision of the Ministry of Health regarding the appeal of the appelant Union of Health Insurance Companies - the decision is reversed and the issue is referred back for reappraisal.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant Otsuka Pharmaceutical Netherlands B. V., against the decision of the State Institute for Drug Control from 15. 3. 2021, under the no. SUKLS246602/2020:
the remainder of the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health regarding the appeal of the appelant Otsuka Pharmaceutical Netherlands B. V. - the appeal is dismissed and the decision under appeal is upheld.
Pharmeca a.s. provides services in the areas defined by this
legislative framework:
Act No. 48/1997 Coll.,on Public Health Insurance and on Amendments to Some Related Acts, as amended.
Implementing legislations:
Decree
No. 376/2011 Coll., which implements certain provisions of the Public Health
Insurance Act, as amended,
Decree No 384/2007 Coll., on the list of reference groups, as amended,
Decree No 385/2007 Coll., on the list of active substances for adjunct or add-on therapy;
Decree
No. 618/2006 Coll., which issues framework agreements, as amended,
Decree
No. 134/1998 Coll., which issues a list of medical services with point values,
as amended,
Decree No. 527/2021 Coll., on determination of the amount of reimbursement of expenses
for professional acts and the method of determination of the amount of compensation of expenses for professional consultations carried out by the
State Institute for Drug Control under the Public Health Insurance Act, as
amended,
Decree
on the determination of point values, the amount of payments for paid services
and regulatory restrictions - always issued for the current year,
Government Regulation No. 307/2012 Coll., on local and temporal availability of health services, as amended.
Act No. 551/1991 Coll., on the General Health Insurance
Company of the Czech Republic, as amended.
Act No. 280/1992 Coll., on departmental, branch, corporate
and other insurance companies, as amended.
Act No. 592/1992 Coll., on public health insurance premiums,
as amended.
Implementing legislations:
Decree No. 351/2022 Coll., on the transmission of data on the consumption of medicinal products by insured persons of the public health insurance when changing the health insurance company, as amended
Act No. 378/2007 Coll., on Pharmaceuticals, as amended.
Implementing legislations:
Decree No. 228/2008 Coll., on the marketing authorisation of medicinal products, as amended,
Decree No. 84/2008 Coll., on good pharmaceutical practice, detailed conditions of handling pharmaceuticals in pharmacies, healthcare facilities and other operators and facilities supplying medicinal products, as amended,
Decree No. 85/2008 Coll., which lays down a list of active substances and excipients which may be used in the preparation of medicinal products, as amended,
Decree No 226/2008 Coll., on good clinical practice and detailed conditions of clinical trials on medicinal products, as amended,
Decree No. 228/2008 Coll., on the marketing authorisation of medicinal products, as amended,
Decree No. 229/2008 Coll., on the manufacture and distribution of pharmaceuticals, as amended,
Decree
No. 236/2015 Coll., on the determination of conditions for prescription,
preparation, distribution, dispense and use of individually prepared medicinal
products containing cannabis for medical use, as amended,
Decree No. 329/2019 Coll., on prescribing medicinal products in the provision
of health services, as amended,
Decree No. 463/2021 Coll., on the detailed conditions for conducting a clinical trial of medicinal products for human use, as amended.
Act No 167/1998Coll, on addictive substances and amending certain other acts, as amended
Implementing legislations:
Decree No. 53/2014 Coll., on forms under the Addictive Substances Act, as amended,
Decree No. 123/2006 Coll., on evidence and documentation of addictive substances and preparations, as amended,
Decree No. 243/2009 Coll., on establishing a list of persons indicating their workplaces for their work is not required permit to treatment of addictive substances and preparations containing them, as amended,
Government
Regulation No. 463/2013 Coll., on lists of addictive substances, as amended,
Decree No. 235/2022 Coll., on the cultivation and processing of cannabis plants for medicinal use, as amended,
Decree No 53/2022 Coll., on the determination of the amount of compensation of expenses for professional acts performed by the State Institute for Drug Control pursuant to the Act on Addictive Substances, as amended.
Act No. 375/2022 Coll., on medical devices and in vitro diagnostic medical devices, as amended.
Implementing legislations:
Decree No 377/2022 Coll., on the implementation of certain provisions of the Act on medical devices and in vitro diagnostic medical devices, as amended,
Decree No 379/2022 Coll., on the determination of the amount of compensationof expenses for professional acts performed by the State Institute for Drug Control pursuant to the Act on Medical Devices and In Vitro Diagnostic Medical Devices, as amended.
Act No 376/2022 Coll. amending certain acts in connection with the adoption of the Act on medical devices and in vitro diagnostic medical devices, as amended.
Act No.268/2014 Coll.,on medical devices and amending Act No. 634/2004 Coll., on administrative fees, as amended.
Act No. 89/2021 Coll., on medical devices and amending Act No. 378/2007 Coll., on pharmaceuticals and on amendments to certain related acts (Act on pharmaceuticals), as amended.
Act No. 22/1997 Coll., on Technical Requirements for Products and amendments to some related acts, as amended.
Act No. 90/2016 Coll., on the assessment of the conformity
of specified products when they are placed on the market, as amended.
Act No. 372/2011 Coll., on health services and conditions for their provision (the Health Services Act), as amended.
Decree
No. 373/2016 Coll., on the transfer of data to the National Health Information System,
as amended.
Act No. 40/1995 Coll., on the regulation of advertising and on amending and supplementing Act No. 468/1991 Coll., on the operation of radio and television broadcasting, as amended.
Act No 242/2022 Coll., on the services of video sharing platforms and amending certain related acts (Act on the services of video sharing platforms), as amended.
Act No. 500/2004 Coll., Administrative Code, as amended.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant Ipsen Pharma S.A.S., against the decision of the State Institute for Drug Control from 12. 3. 2021, under the no. SUKLS306733/2020:
the decision under
appeal is reversed and the issue is referred back to the State Institute for
Drug Control for reappraisal.
A decision of the Ministry of Health regarding the appeal of the appelant Ipsen Pharma S.A.S. - the decision is reversed and the issue is referred back for reappraisal.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant Union of Health Insurance Companies, against the decision of the State Institute for Drug Control from 29. 3. 2021, under the no. SUKLS265370/2018:
the remainder of the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health regarding the appeal of the appelant Union of Health Insurance Companies - the appeal is dismissed and the decision under appeal is upheld.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant Union of Health Insurance Companies, against the decision of the State Institute for Drug Control from 18. 8. 2020, under the no. SUKLS48287/2022:
the decision under
appeal is reversed and the issue is referred back to the State Institute for
Drug Control for reappraisal.
A decision of the Ministry of Health regarding the appeal of the appelant Union of Health Insurance Companies - the decision is reversed and the issue is referred back for reappraisal.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelant Union of Health Insurance Companies, against the decision of the State Institute for Drug Control from 17. 12. 2020, under the no. SUKLS225105/2020:
the decision under
appeal is reversed and the issue is referred back to the State Institute for
Drug Control for reappraisal.
A decision of the Ministry of Health regarding the appeal of the appelant Union of Health Insurance Companies - the decision is reversed and the issue is referred back for reappraisal.
A decision of the Ministry of Health of the Czech Republic regarding the appeal of the appelants Gedeon Richter Plc., against the decision of the State Institute for Drug Control from 2. 11. 2022, under the no.: SUKLS25072/2022:
the decision is reversed and the proceedings are terminated.
A decision of the Ministry of Health regarding the appeal of the appelants Gedeon Richter Plc. - the decision is reversed and the proceedings are terminated.